182 related articles for article (PubMed ID: 28616661)
41. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients.
Lauwerys BR; Garot N; Renauld JC; Houssiau FA
Arthritis Rheum; 2000 Sep; 43(9):1976-81. PubMed ID: 11014347
[TBL] [Abstract][Full Text] [Related]
42. Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.
Du Y; Wu X; Chen M; Wang W; Xv W; Ye L; Wu D; Xue J; Sun W; Luo J; Wu H
Clin Exp Immunol; 2017 May; 188(2):234-242. PubMed ID: 28063160
[TBL] [Abstract][Full Text] [Related]
43. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
von Spee-Mayer C; Siegert E; Abdirama D; Rose A; Klaus A; Alexander T; Enghard P; Sawitzki B; Hiepe F; Radbruch A; Burmester GR; Riemekasten G; Humrich JY
Ann Rheum Dis; 2016 Jul; 75(7):1407-15. PubMed ID: 26324847
[TBL] [Abstract][Full Text] [Related]
44. Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Sipka S; Szucs K; Szántó S; Kovács I; Lakos G; Kiss E; Antal-Szalmás P; Szegedi G; Gergely P
Ann Rheum Dis; 2001 Apr; 60(4):380-4. PubMed ID: 11247869
[TBL] [Abstract][Full Text] [Related]
45. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.
Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X
Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325
[TBL] [Abstract][Full Text] [Related]
46. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
47. The Role of CXC Chemokines in Pulmonary Fibrosis of Systemic Lupus Erythematosus Patients.
Nielepkowicz-Goździńska A; Fendler W; Robak E; Kulczycka-Siennicka L; Górski P; Pietras T; Brzeziańska E; Pietrusińska M; Antczak A
Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):465-73. PubMed ID: 26275808
[TBL] [Abstract][Full Text] [Related]
48. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?
Catoggio LJ; Soriano ER; Imamura PM; Wojdyla D; Jacobelli S; Massardo L; Chacón Díaz R; Guibert-Toledano M; Alvarellos A; Saurit V; Manni JA; Pascual-Ramos V; Silva de Sauza AW; Bonfa E; Tavares Brenol JC; Ramirez LA; Barile-Fabris LA; De La Torre IG; Alarcón GS; Pons-Estel BA;
Lupus; 2015 Jul; 24(8):788-95. PubMed ID: 25504653
[TBL] [Abstract][Full Text] [Related]
49. Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy.
Doria A; Iaccarino L; La Montagna G; Mathieu A; Piga M; Galeazzi M; Iuliano A; Maurel FB; Garofano AM; Perna AG; Porcasi RE
Clin Exp Rheumatol; 2015; 33(3):375-84. PubMed ID: 26005879
[TBL] [Abstract][Full Text] [Related]
50. A simple method for removing low-density granulocytes to purify T lymphocytes from peripheral blood mononuclear cells.
Zhang SG; Song YX; Shu XM; Shen HL; Yang HB; Duo RX; Wang GC
J Zhejiang Univ Sci B; 2017 Jul; 18(7):605-614. PubMed ID: 28681585
[TBL] [Abstract][Full Text] [Related]
51. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
52. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
[TBL] [Abstract][Full Text] [Related]
53. Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.
Durcan L; Winegar DA; Connelly MA; Otvos JD; Magder LS; Petri M
J Rheumatol; 2016 Apr; 43(4):745-50. PubMed ID: 26834214
[TBL] [Abstract][Full Text] [Related]
54. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
55. Vitamin D3 Alters the Expression of Toll-like Receptors in Peripheral Blood Mononuclear Cells of Patients With Systemic Lupus Erythematosus.
Yazdanpanah E; Mahmoudi M; Sahebari M; Rezaieyazdi Z; Esmaeili SA; Tabasi N; Jaberi S; Sahebkar A; Rastin M
J Cell Biochem; 2017 Dec; 118(12):4831-4835. PubMed ID: 28544067
[TBL] [Abstract][Full Text] [Related]
56. Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register.
Sousa S; Gonçalves MJ; Inês LS; Eugénio G; Jesus D; Fernandes S; Terroso G; Romão VC; Cerqueira M; Raposo A; Couto M; Nero P; Sequeira G; Nóvoa T; Melo Gomes JA; da Silva JC; Costa L; Macieira C; Silva C; Silva JA; Canhão H; Santos MJ
Rheumatol Int; 2016 Jul; 36(7):955-60. PubMed ID: 26979603
[TBL] [Abstract][Full Text] [Related]
57. Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro.
Wirestam L; Enocsson H; Skogh T; Eloranta ML; Rönnblom L; Sjöwall C; Wetterö J
Clin Exp Immunol; 2017 Jul; 189(1):83-91. PubMed ID: 28257596
[TBL] [Abstract][Full Text] [Related]
58. Neutrophil-binding immunoglobulin G in systemic lupus erythematosus.
Starkebaum G; Arend WP
J Clin Invest; 1979 Oct; 64(4):902-12. PubMed ID: 479375
[TBL] [Abstract][Full Text] [Related]
59. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity.
Su CC; Shau WY; Wang CR; Chuang CY; Chen CY
Lupus; 1997; 6(5):449-54. PubMed ID: 9229364
[TBL] [Abstract][Full Text] [Related]
60. Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus.
Moonen JR; de Leeuw K; van Seijen XJ; Kallenberg CG; van Luyn MJ; Bijl M; Harmsen MC
Arthritis Res Ther; 2007; 9(4):R84. PubMed ID: 17764548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
